资讯

Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...
American Association of Individual Investors4 小时
Why Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 5.78%
Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 5.78%, which has investors questioning if this is right time to ...
Eli Lilly jumps as oral GLP-1 drug succeeds in Phase 3 trial
Eli Lilly's (LLY) stock surges 14% as its diabetes drug orforglipron meets Phase 3 goals, cutting weight by 8%. Read more ...
CURE9 天
Breaking Down The Use of Rina-S in Advanced Ovarian Cancer
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Using a pea-sized node in the brain to potentially treat drug addiction: Q&A
Major scientific discoveries can arise from simple decisions: say, by simply looking where virtually no one else has. Such ...
American Association of Individual Investors3 天
Why Relay Therapeutics, Inc.’s (RLAY) Stock Is Up 5.63%
Relay Therapeutics, Inc.’s RLAY share price has surged by 5.63%, which has investors questioning if this is right time to sell.
MedPage Today on MSN7 天
FDA Approves New Option for Chronic Hives
The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...
Dermatology Advisor3 天
Dupixent Approved for Chronic Spontaneous Urticaria
The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.
Medscape5 天
Oral Serotonin Type 3-Receptor Antagonists For Prevention of Chemotherapy-Induced Emesis
The theoretical basis for and clinical experience with using oral serotonin type 3 (5-HT 3)-receptor antagonists for preventing chemotherapy-induced emesis are discussed. Evidence supports the ...